Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
Introduced
Jan 9, 2025
Last Action
Mar 21, 2025
Session
IL 104th
Sponsors
1 primary · 0 co
House Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee
Rule 19(a) / Re-referred to Rules Committee
House Committee Amendment No. 1 Rules Refers to Insurance Committee
House Committee Amendment No. 1 Filed with Clerk by Rep. Jed Davis
House Committee Amendment No. 1 Referred to Rules Committee
To Insurance Main Subcommittee
Assigned to Insurance Committee
First Reading
Referred to Rules Committee
Prefiled with Clerk by Rep. Jed Davis
Get a plain-English explanation of what this bill does, who it affects, and why it matters.
House Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee